Abstract:Disease associated pathological aggregates of alpha-synuclein (αSyn D ) exhibit prion-like spreading in synucleinopathies such as Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Seed amplification assays (SAAs) such as real-time quaking-induced conversion (RT-QuIC) have shown high diagnostic sensitivity and specificity for detecting proteopathic αSyn D seeds in a variety of biospecimens from PD and DLB patients. However, the extent to which relative proteopathic seed concentrations are useful as indices of a patient's disease stage or prognosis remains unresolved. One feature of current SAAs that complicates attempts to correlate SAA results with patients' clinical and other laboratory findings is their quantitative imprecision, which has typically been limited to discriminating large differences (e.g. 5–10 fold) in seed concentration. We used end-point dilution (ED) RT-QuIC assays to determine αSyn D seed concentrations in patient biospecimens and tested the influence of various assay variables such as serial dilution factor, replicate number and data processing methods. The use of 2-fold versus 10-fold dilution factors and 12 versus 4 replicate reactions per dilution reduced ED-RT-QuIC assay error by as much as 70%. This enhanced assay format discriminated as little as 2-fold differences in αSyn D seed concentration besides detecting ~2-16-fold seed reductions caused by inactivation treatments. In some scenarios, analysis of the data using Poisson and midSIN algorithms provided more consistent and statistically significant discrimination of different seed concentrations. We applied our improved assay strategies to multiple diagnostically relevant PD and DLB antemortem patient biospecimens, including cerebrospinal fluid, skin, and brushings of the olfactory mucosa. Using ED αSyn RT-QuIC as a model SAA, we show how to markedly improve the inter-assay reproducibility and quantitative accuracy. Enhanced quantitative SAA accuracy should facilitate assessments of pathological seeding activities as biomarkers in proteinopathy diagnostics and prognostics, as well as in patient cohort selection and assessments of pharmacodynamics and target engagement in drug trials. Seed amplification assays (SAAs) such as RT-QuIC detect pathological α-Syn aggregates with prion-like self-propagating (seeding) activity from various tissue biospecimens of synucleinopathy patients. However, clinical applications of current SAAs to neurodegenerative diseases can be hampered by their quantitative imprecision in stratifying levels of pathological seeds as biomarkers. In this study, we tested the influence of various assay variables including dilution factor, number of replicates, and quantitation methods in end-point dilution RT-QuIC (ED RT-QuIC) using PD and DLB patient samples, specifically brain tissue, CSF, skin, and nasal brushings. Our study highlights how assay design can markedly improve seed quantification in clinical samples. Better proteopathic seed quantification should enable more precise evaluation of pathological seeding activity to support important clinical and research applications.

Improving protocols for α-synuclein seed amplification assays: analysis of preanalytical and analytical variables and identification of candidate parameters for seed quantification

Enhanced quantitation of pathological α-synuclein in patient biospecimens by RT-QuIC seed amplification assays

Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden

Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC

Pathological α-synuclein detected by real-time quaking-induced conversion in synucleinopathies

High-Yield α-Synuclein Purification and Ionic Strength Modification Pivotal to Seed Amplification Assay Performance and Reproducibility

Propagative α-synuclein seeds as serum biomarkers for synucleinopathies

Quantitative Seed Amplification Assay: A Proof-of-Principle Study

α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward

Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies

The amplification of alpha‐synuclein amyloid fibrils is suppressed under fully quiescent conditions

Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson’s disease and dementia with Lewy bodies

Towards an improved early diagnosis of neurodegenerative diseases: the emerging role of in vitro conversion assays for protein amyloids

The secondary nucleation of alpha-synuclein amyloid fibrils is suppressed under fully quiescent conditions

Seed amplification and RT-QuIC assays to investigate protein seed structures and strains

RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies

CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease

Misfolded alpha-synuclein detection by RT-QuIC in dementia with lewy bodies: a systematic review and meta-analysis

Development of α-Synuclein Real-Time Quaking-Induced Conversion as a Diagnostic Method for α-Synucleinopathies

Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes

Blood-based Nano-QuIC: Inhibitor-resistant Detection of Seeding Activity in Patients Diagnosed with Parkinson Disease